Advertisement

Topics

Companies Related to "IMT in Hypercapnic Patients With COPD" [Most Relevant Company Matches] RSS

19:53 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "IMT in Hypercapnic Patients With COPD" found in our extensive corporate database of over 50,000 company records.

Showing "Hypercapnic Patients With COPD" Companies 1–25 of 3,700+

Relevant

EPIGENSISPHARMACEUTICALS

EPIGENSISPHARMACEUTICALSDevelop inhaled respiratory medicines that are safe, effective and improve the health and quality of life in patients with asthma, obstructive pulmonary disease (COPD), and other respiratory diseases. Develop inhaled respiratory medicines with commercially attractive target product profiles that address the unmet medical needs of patients with asthma and COPD, two of the l...


Hunter Immunology Limited

Our lead product is a vaccine currently called HI-164OV. It works by controlling bacterial colonisation of airways damaged by inhaled toxins. It has been developed to treat patients with Chronic Obstructive Pulmonary Disease (COPD) which includes bronchitis and emphysema. HI-164OV could help improve the lives of over one million Australians with COPD, and contribute towards saving Australia ...

The COPD Foundation

The mission of the COPD Foundation is to develop and support programs, which improve the quality of life through research, education, early diagnosis and enhanced therapy for persons whose lives are impacted by Chronic Obstructive Pulmonary Disease.


Topigen Pharmaceuticals Inc.

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and aller...

Theron Pharmaceuticals, Inc.

Headquartered in Sunnyvale, California, Theron Pharmaceuticals is committed to developing improved treatments for COPD and asthma. COPD is a slowly developing progressive small airways disease comprised broadly of chronic bronchitis and emphysema, and characterized by airflow limitation and decreased lung function. COPD is a major and growing health concer...

COPD Foundation

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the U.S. and the only chronic disease growing in mortality. It affects approximately 24 million Americans but only 12 million are diagnosed. COPD includes chronic bronchitis, emphysema, and adult onset (refractory) asthma. Symptoms include breathlessness, wheezing, and chr...

DRIVE4COPD

Launched in February 2010, DRIVE4COPD is a landmark public health movement embraced by leading health, business, entertainment and sports organizations that are aimed at driving fundamental change in COPD awareness in this country. This initiative aims to help millions of people affected by COPD by focusing national attention on this common and debilitating disease.

National Emphysema/COPD Association

COPD Foundation and the New York Mets

iGetBetter, Inc.

Established in 2013, iGetBetter, Inc. develops, markets and services a Web-based care transition solution designed to help healthcare organizations reduce readmissions by remotely engaging patients in their treatments and recovery as they transition from hospital to home. Based in Waltham, Massachusetts, the iGetBetter’s team of clinicians, technologi...

Elevation Pharmaceuticals, Inc.

Elevation Pharmaceuticals is a biopharmaceutical company focused on developing new inhaled therapies for patients with respiratory disease. The Company was founded in 2008 by Cam Garner, formerly Chairman and CEO of Dura Pharmaceuticals, Bill Gerhart, formerly President and CEO of Mpex Pharmaceuticals, and Ahmet Tutuncu, formerly VP of Medical Affairs at Verus Pharmaceuticals. The Company's init...

Ario Pharma Ltd

ario pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease. Co...

Probably Relevant

The Alpha-1 Project

Mission statement: The Alpha-1 Project will work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the relentless pursuit of cures and therapies for COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency. For more information, visit www.thealpha-1project.com. The Alpha-1 Project is a wholly-owned for...

Rotech Healthcare Inc.

Rotech Healthcare Inc. is one of the largest providers of home medical equipment and related products and services in the United States, with a comprehensive offering of respiratory therapy and durable home medical equipment and related services. The Company provides home medical equipment and related products and services principally to older patients wit...

Pearl Therapeutics Inc.

Pearl Therapeutics is developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals ...

Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases.  HI-164OV, in Phase IIb clinica...

West Coast Clinical Trials, LLC

West Coast Clinical Trials, LLC is a thriving research practice with an active adult and pediatric unit. The corporate office is located in Costa Mesa which also houses a 30 bed unit. Our second office is a 25,000 square foot facility located in Long Beach, California. We specialize in allergy, asthma, hypertension, diabetes, cholesterol, dermatology, COPD, upper respiratory studies, pediatric and...

Innoviva, Inc.

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA...

Pulmatrix, Inc.

Pulmatrix, Inc., is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix’s lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM™), are a novel approach to prevent and treat acute exacerbations an...

Chad Therapeutics

We are the innovators and manufacturers of cost efficient, user friendly stationary and ambulatory oxygen systems designed for use by patients diagnosed with COPD and other respiratory disorders. As the leader in oxygen conservation, we take pride in providing some of the lightest weight, longest lasting portable oxygen systems available today. It is the innovative technology of our extensive li...

Amakem

Amakem NV is a biopharmaceutical company developing safe and effective kinase inhibitors using its "Localized Drug Action" platform for the treatment of diseases, such as COPD, glaucoma and inflammatory bowel disease. The company focuses on the development of promising and innovative near clinical or clinical small molecule drugs.

The Patients Association

The Patients Association is a registered charity, staffed by paid and unpaid staff. The Patients Association offers patients an opportunity to share their experiences of health services. The Patients Association uses the knowledge it gains from patients to work with the NHS and other healthcare providers to improve services. The Patients Association works with a range of organisations providing he...

PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration customized with advanced delivery platforms, such as eFlow (lower respiratory) and...

Spiros Development Corporation

Spiros Development Corporation develops the Spiros-Registered Trademark-, a dry powder pulmonary drug delivery system, and to conduct formulation work, clinical trials and commercialization for certain specified leading asthma and chronic obstructive pulmonary disease ("COPD") drugs for use with Spiros.

MicroDose Technologies, Inc.

MicroDose Technologies, Inc. is a privately held premier drug delivery and specialty pharmaceuticals company. Founded in 1998, MicroDose is pioneering the use of proprietary drug delivery platforms for the pulmonary, oral and transdermal delivery of medications for improved efficacy and compliance. MicroDose's current focus is on the chronic disease states such as asthma, COPD, diabetes, hypertens...


More From BioPortfolio on "IMT in Hypercapnic Patients With COPD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks